CN104837482B - 纳米颗粒制剂 - Google Patents

纳米颗粒制剂 Download PDF

Info

Publication number
CN104837482B
CN104837482B CN201380055336.1A CN201380055336A CN104837482B CN 104837482 B CN104837482 B CN 104837482B CN 201380055336 A CN201380055336 A CN 201380055336A CN 104837482 B CN104837482 B CN 104837482B
Authority
CN
China
Prior art keywords
nanoparticle formulations
formulations according
lita
nanoparticles
phosphatidyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380055336.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN104837482A (zh
Inventor
吉米·贝尔
伊丽莎白-路易丝·托马斯
利·布罗迪
迈利兹-萨胡里·阿里索鲁
安德鲁·米勒
加里·佛洛斯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical Research Council
United Kingdom Research and Innovation
Original Assignee
Creative Co Of Kingdom
Medical Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Creative Co Of Kingdom, Medical Research Council filed Critical Creative Co Of Kingdom
Publication of CN104837482A publication Critical patent/CN104837482A/zh
Application granted granted Critical
Publication of CN104837482B publication Critical patent/CN104837482B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380055336.1A 2012-08-28 2013-08-28 纳米颗粒制剂 Active CN104837482B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1215289.8A GB201215289D0 (en) 2012-08-28 2012-08-28 Nanoparticle formulation
GB1215289.8 2012-08-28
PCT/GB2013/052258 WO2014033453A1 (en) 2012-08-28 2013-08-28 Nanoparticle formulation

Publications (2)

Publication Number Publication Date
CN104837482A CN104837482A (zh) 2015-08-12
CN104837482B true CN104837482B (zh) 2018-09-18

Family

ID=47045497

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380055336.1A Active CN104837482B (zh) 2012-08-28 2013-08-28 纳米颗粒制剂

Country Status (8)

Country Link
US (1) US10201499B2 (OSRAM)
EP (1) EP2890365B1 (OSRAM)
JP (1) JP6483017B2 (OSRAM)
CN (1) CN104837482B (OSRAM)
AU (1) AU2013308245B2 (OSRAM)
CA (1) CA2882705C (OSRAM)
GB (1) GB201215289D0 (OSRAM)
WO (1) WO2014033453A1 (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8962015B2 (en) 2007-09-28 2015-02-24 Sdg, Inc. Orally bioavailable lipid-based constructs
US20160158174A1 (en) * 2014-12-09 2016-06-09 Intercontinental Great Brands Llc Enteric-Coated Functional Food Ingredients And Methods For Making The Enteric-Coated Functional Food Ingredients
RU2017127597A (ru) * 2015-01-23 2019-02-25 Темпл Юнивёрсити-Оф Дзе Коммонвелс Систем Оф Хайе Эдьюкейшен Применение короткоцепочечных жирных кислот для профилактики рака
CN106551902B (zh) * 2015-09-17 2020-07-03 阿赖耶识（上海）生物技术有限公司 一种高稳定的非囊泡型纳米颗粒及其在治疗微生物感染中的应用
CN105669964B (zh) * 2016-03-04 2017-11-21 博瑞生物医药（苏州）股份有限公司 卵巢癌特异靶向的生物可降解双亲性聚合物、由其制备的聚合物囊泡及应用
US11065217B2 (en) 2017-01-27 2021-07-20 Temple University—Of the Commonwealth System of Higher Education Use of short chain fatty acids for the treatment and prevention of diseases and disorders
US11077173B2 (en) 2017-03-13 2021-08-03 Sdg, Inc. Lipid-based nanoparticles and methods using same
AU2018236190B2 (en) * 2017-03-13 2025-02-20 Sdg, Inc. Lipid-based nanoparticles with enhanced stability
CN110891982B (zh) 2017-04-17 2023-12-22 芝加哥大学 向肠道递送短链脂肪酸以用于人体保健和疾病治疗的聚合物材料
CN107049954A (zh) * 2017-06-12 2017-08-18 杭州普施康生物科技有限公司 一种药物组合及其制备方法和用途
CN110192651A (zh) * 2019-05-31 2019-09-03 浙江工业大学 一种利用大豆分离蛋白负载植物甾醇酯的纳米乳液的制备方法
CN111426659B (zh) * 2020-03-24 2023-06-06 深圳唯公生物科技有限公司 磁性荧光编码微球及其制备方法
US20250269003A1 (en) * 2022-04-22 2025-08-28 University Of Virginia Patent Foundation Nano-enhanced vaccine
KR20250107214A (ko) * 2022-11-10 2025-07-11 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 간질환 또는 간장애의 치료 또는 예방 방법
CN118105524B (zh) * 2024-03-14 2024-11-22 南京鼓楼医院 一种靶向肠上皮细胞的焦亡抑制剂药物递送系统及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000030620A1 (en) * 1998-11-25 2000-06-02 Maria Rosa Gasco Solid lipidic nanospheres suitable to a fast internalization into cells
CN102216462A (zh) * 2008-11-17 2011-10-12 安龙制药公司 用于核酸递送系统的支化阳离子脂质

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6441025B2 (en) * 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
DE69727384T2 (de) * 1996-05-24 2004-11-04 IC-VEC Ltd. Polykatonische sterin-derivate zur transfektion
US6146847A (en) * 1996-11-01 2000-11-14 Genespan Corporation Stabilized transient gene expression
EP1140022B8 (en) * 1998-12-18 2008-10-15 Hadasit Medical Research Services & Development Ltd. Method of administering a compound to multi-drug resistant cells
US6387952B1 (en) 2000-09-19 2002-05-14 Arco Chemical Technology L.P. Method of treating gastrointestinal disorders, particularly colitis
WO2003030864A1 (en) * 2001-05-29 2003-04-17 Neopharm, Inc. Liposomal formulation of irinotecan
WO2006007634A1 (en) 2004-07-16 2006-01-26 Cerylid Biosciences Ltd Processes and intermediates
WO2006076734A2 (en) 2005-01-14 2006-07-20 Medical College Of Georgia Research Institute Prodrugs of short-chain fatty acids and treatment methods
US9315532B2 (en) 2005-05-24 2016-04-19 The Johns Hopkins University Fatty acid carbohydrate hybrid molecules as therapeutic agents and methods thereof
ITMI20051024A1 (it) 2005-06-01 2006-12-02 Maria Rosa Gasco Nuovo uso di nanoparticelle lipidiche solide
US7700567B2 (en) * 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
CA2673622A1 (en) 2006-12-22 2008-07-03 Imuthes Limited Lipid

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000030620A1 (en) * 1998-11-25 2000-06-02 Maria Rosa Gasco Solid lipidic nanospheres suitable to a fast internalization into cells
CN102216462A (zh) * 2008-11-17 2011-10-12 安龙制药公司 用于核酸递送系统的支化阳离子脂质

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Folate Receptor Targeted Bimodal Liposomes for Tumor Magnetic Reconance Imaging;Nazila Kamaly等;《Bioconjugate Chem.》;20091003;第20卷(第4期);第648-655页 *
Novel applications of liposomes;Dan D.Lasic;《TIBTECH》;19980731;第16卷;第307-321页 *

Also Published As

Publication number Publication date
EP2890365A1 (en) 2015-07-08
GB201215289D0 (en) 2012-10-10
AU2013308245B2 (en) 2018-03-29
EP2890365B1 (en) 2019-11-20
CN104837482A (zh) 2015-08-12
CA2882705C (en) 2021-06-22
AU2013308245A1 (en) 2015-04-09
JP2015530382A (ja) 2015-10-15
US20150224054A1 (en) 2015-08-13
US10201499B2 (en) 2019-02-12
WO2014033453A1 (en) 2014-03-06
JP6483017B2 (ja) 2019-03-13
HK1211862A1 (en) 2016-06-03
CA2882705A1 (en) 2014-03-06

Similar Documents

Publication Publication Date Title
CN104837482B (zh) 纳米颗粒制剂
JP6392209B2 (ja) 粘液内層を通過する迅速な透過のための脂質ベース薬物キャリア
Kong et al. Cationic solid lipid nanoparticles derived from apolipoprotein-free LDLs for target specific systemic treatment of liver fibrosis
Cheong et al. Superparamagnetic iron oxide nanoparticles-loaded chitosan-linoleic acid nanoparticles as an effective hepatocyte-targeted gene delivery system
CN110522917A (zh) 一种甘露糖修饰的靶向纳米制剂
JP2004511426A5 (OSRAM)
JP2020528432A (ja) 弱酸性薬物を含むリポソーム組成物およびその使用
JP2006528700A (ja) 肥満の治療のためのカテコールブタンの投与のための方法と組成物
WO2013188767A1 (en) Method and system for measuring the pharmacokinetics of liposomal curcumin and its metabolite tetrahydrocurcumin
JP6230538B2 (ja) 安定なオキサリプラチン封入リポソーム水分散液及びその安定化方法
US6562371B1 (en) Liposomes
US11213573B2 (en) Particles comprising surfactant protein B and one or more lipids
US20140161733A1 (en) Biomarker-targeting contrast agents and their use in magnetic resonance imaging for detection of atherosclerotic plaque
CN1980671B (zh) 含有水难溶性喜树碱的脂质体制剂
Liu et al. Glucagon-modified liposomes delivering thyroid hormone for anti-obesity therapy
CN113307824B (zh) 一种双亲性材料及其在制备脂质体中的应用
HK1211862B (en) Nanoparticle formulation
Yu et al. Targeted delivery of empagliflozin via glycyrrhetinic-acid-modified lipid nanoparticles for metabolic dysfunction–associated steatotic liver disease therapy
JP4904573B2 (ja) 目的物質の脳毛細血管内皮細胞への取り込みを亢進させるための組成物
WO2012153616A1 (ja) 標的細胞移行能を有する脂質膜構造体、その製造方法および標的細胞において効果を示す物質のスクリーニング方法
WO2024206230A1 (en) Tissue targeting lipids and lipid nanoparticles
WO2022198124A1 (en) Red-shifted photolipids and nanoparticles formed from same
CN119564667A (zh) 一种用于动脉粥样硬化斑块靶向诊断及治疗的纳米药物
KR101591573B1 (ko) 개선된 암의 ct 이미징 획득하는 방법
CN118891048A (zh) 放射增敏组合物及其使用方法

Legal Events

Date Code Title Description
PB01 Publication
EXSB Decision made by sipo to initiate substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20200110

Address after: UK

Patentee after: United Kingdom Research and Innovation

Address before: Swindon, Wiltshire, UK

Patentee before: Medical Research Council

Effective date of registration: 20200110

Address after: Swindon, Wiltshire, UK

Patentee after: MEDICAL RESEARCH COUNCIL

Address before: England

Co-patentee before: IMP INNOVATIONS LTD.

Patentee before: Medical Research Council

TR01 Transfer of patent right